Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25523624 | 0.82 | HDAC1 (0.39) | HDAC1HDAC8HDAC6SSTR4HDAC3 | |
| SCHEMBL23774916 | 0.82 | USP30 (0.34) | HDAC1HDAC8HDAC6USP30 | |
| SCHEMBL25523616 | 0.80 | SSTR4 (0.42) | HDAC1HDAC8HDAC6SSTR4HDAC3 | |
| SCHEMBL31398614 | 0.77 | HDAC1 (0.34) | HDAC1HDAC8HDAC6USP30HTR2C | |
| SCHEMBL23774900 | 0.73 | SSTR4 (0.42) | HDAC1HDAC8HDAC6SSTR4HDAC3 | |
| SCHEMBL6018000 | 0.71 | HDAC3 (0.43) | HDAC1SSTR4HDAC3HDAC2NCOR2 | |
| SCHEMBL6018387 | 0.70 | CYP1A2 (0.40) | HDAC1SSTR4HDAC3HDAC2NCOR2 | |
| SCHEMBL6017972 | 0.70 | HDAC3 (0.41) | HDAC1HDAC3HDAC2NCOR2POLB | |
| SCHEMBL23757860 | 0.70 | LMNA (0.32) | — | |
| SCHEMBL27439189 | 0.68 | TRPM8 (0.55) | HDAC1SSTR4HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | HDAC1 35/4885HDAC8 145/4885HDAC6 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.